Welcome to hematology

We are attending Syyskoulutuspäivien ohjelma 2023 and will keep you posted with MEDtalks, abstracts and articles from September 28th.

Stay updated

Update your profile

We’ve split our coverage of oncology and hematology into two dedicated subsites.
Update your profile – with the specialty you’re interested in.

Go to profile

The Epidemiology and Genetics of Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

Onkologiapäivät23

DLBCL

Play the Video
3:31

September 2023 / Ilja Kalashnikov

A short update on aggressive lymphoma

September 2023 / Hanne Kuitunen

Lymphoma Onkologiapäivät23

Magazine

Oncology / Hematology • No. 14 • 2023

Breast Cancer: The Future of HER2-Low Treatment
Lung Cancer: Pretreatment Platelet Count a Prognostic Marker
Multiple Myeloma: Belamaf and Dexamethasone – Safe, Effective Treatment
CLL: Small-Molecule Inhibitor Sequencing and Combination Therapies

Get access

Clinical Editorial Board

Heikki Minn

Professori, ylilääkäri Turun yliopistollinen sairaala, Syöpätautien klinikka

Taina Turpeenniemi-Hujanen

Professori, ylilääkäri Oulun yliopisto sekä Oulun yliopistollinen sairaala, Syöpätautien toimialue

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

June 2023 / Hematology / BestPractice Nordic

High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma

June 2023 / Oncology / Katrine Fladeland Iversen

An update on new treatments for acute myeloid leukemia

April 2023 / Hematology / Hans Beier Ommen

Late-breaking from ASH22 – Let’s keep the standard consolidation therapy with HDC-ASCT for PCNSL patients

December 2022 / Hematology / BestPractice Nordic

Late-breaking from ASH22 – Zanubrutinib has now proven superiority to ibrutinib

December 2022 / Hematology / BestPractice Nordic

Se oversigt

ASH22 – Building Solutions to Challenges in Health Equity

ASH22

December 2022 / BestPractice Nordic

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

We are attending Syyskoulutuspäivien ohjelma 2023 and will keep you posted with MEDtalks, abstracts and articles from September 28th.

Update your profile

The Epidemiology and Genetics of Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

A short update on aggressive lymphoma

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

Belamaf shows deeper, longer-lasting myeloma response

EHA 2023: Professor Pieter Van Vlierberghe Posthumously Decorated with David Grimwade Award

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

Evolving Concepts in Chronic Lymphocytic Leukemia (CLL) – Optimizing Treatment Strategies and Patient Experience

Epcoritamab with rituximab and lenalidomide (R2) for patients with high-risk follicular lymphoma

Gilteritinib for patients with newly diagnosed AML

MURANO study supports the use of fixed-duration VenR in R/R CLL

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

News from EHA23 – A promising treatment option for follicular lymphoma

Magazine

Oncology / Hematology • No. 14 • 2023

Clinical Editorial Board

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma

An update on new treatments for acute myeloid leukemia

Late-breaking from ASH22 – Let’s keep the standard consolidation therapy with HDC-ASCT for PCNSL patients

Late-breaking from ASH22 – Zanubrutinib has now proven superiority to ibrutinib

ASH22 – Building Solutions to Challenges in Health Equity

Name & work area

We are attending Syyskoulutuspäivien ohjelma 2023 and will keep you posted with MEDtalks, abstracts and articles from September 28th.

Update your profile

Articles

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

Belamaf shows deeper, longer-lasting myeloma response

EHA 2023: Professor Pieter Van Vlierberghe Posthumously Decorated with David Grimwade Award

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

Evolving Concepts in Chronic Lymphocytic Leukemia (CLL) – Optimizing Treatment Strategies and Patient Experience

MEDtalks

Epcoritamab with rituximab and lenalidomide (R2) for patients with high-risk follicular lymphoma

Gilteritinib for patients with newly diagnosed AML

MURANO study supports the use of fixed-duration VenR in R/R CLL

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

News from EHA23 – A promising treatment option for follicular lymphoma

Magazine

Oncology / Hematology • No. 14 • 2023

Clinical Editorial Board

We cover

EHA | Congress Site

ASH | Congress Site

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma

An update on new treatments for acute myeloid leukemia

Late-breaking from ASH22 – Let’s keep the standard consolidation therapy with HDC-ASCT for PCNSL patients

Late-breaking from ASH22 – Zanubrutinib has now proven superiority to ibrutinib

Latest MEDtalk from hematology

More from hematoloogy